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(MakerGear, M2). The infill settings were chosen so that the 
resulting models would be very rigid and durable. Using a 
hammer, a 3 mm thick, layer of lead was bent to fit the contours 
of the model. A hole was then cut out to define the field, and 
the lead was clear coated. 
Results: The lead shields created were remarkably accurate and 
fit the contours of the patients. The hole cut to define the field 
exposed only a minimally sized site to be irradiated. The rest of 
the face, including vulnerable OAR, were protected. The length 
of time during which the patient’s presence was required was 
minimal, as was the time spent by staff to create the mask. 
Conclusions: Using this technology to create lead shielding for 
radiotherapy of skin cancer of the face is an innovative and 
exciting approach. This could save valuable clinic time and add 
patient convenience. Some traditional methods require an extra 
appointment to create a facial mould. The optical scan can be 
obtained on the day of the clinical visit with no subsequent visit 
required until first treatment. If there are issues generating the 
lead shield the patient doesn’t need to come in for another visit; 
the saved 3D optical image can be used to generate another lead 
shield. The cost of manufacture is also low; centres, such as 
those in the developing world that may not have the 
infrastructure to treat skin cancer with electrons could use this 
method to safely deliver ortho-voltage treatments. A significant 
number of patients suffer from claustrophobia, and this could be 
addressed by using this technology. 
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CAN WE REDUCE NORMAL TISSUE RADIATION EXPOSURE? – A 
CRANIOSPINAL IRRADIATION TECHNIQUE WITHOUT JUNCTION 
MATCHING USING VARIAN ECLIPSE PLATFORM 
Laura Drever, Vijayananda Kundapur  
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Purpose: Medulloblastoma most frequently occurs in the 
pediatric age group and craniospinal irradiation (CSI) is a 
standard component of management. CSI is technically 
challenging due to the possibility of multiple junctions, each 
with shifts, required to treat the craniospinal axis; more so if the 
patient requires anesthesia. Several techniques are described in 
the literature addressing how to avoid junctions however the use 
of those techniques for all comers is an issue. The aim of this 
work is to develop a simple image guided IMRT technique for CSI 
on the Varian Eclipse platform, deliverable on Varian linacs, with 
intrafraction modulated junctions while reducing dose to normal 
structures. 
Methods and Materials: Using Varian treatment planning 
software and linacs the proposed technique sets one table height 
and one lateral position for all plans as well as allows for imaging 
of each of the two or three isocentres to verify patient set up. 
Further, the spinal axis is treated using three IMRT fields which 
allows for increased dose homogeneity while limiting the amount 
of patient volume being treated to a low dose, while the brain is 
treated using IMRT with a POP arrangement. 
Results: Using the proposed technique we re-planned patients 
previously treated prone with extended source to skin distance 
(SSD), with field matching on skin. All planning parameters were 
compared. The proposed technique reduced plan maximum dose 
on the order of 10% while also reducing the mean dose to the 
optic structures and heart. The mean dose to the kidneys was 
comparable between techniques while the mean dose to the lung 
was slightly higher with the new technique while the maximum 
dose to the lungs was lower with the new technique. Using the 
new technique, two further patients were scanned and planned 
in supine position. The total PTV length for these patients was 
74 and 56 cm respectively. Delivery of general anesthesia and 
monitoring was easy. 
Conclusions: The proposed technique is a simple to deliver, 
image guided IMRT technique using Varian equipment with 
intrafraction modulated junctions. This technique allows for easy 
set up verification and less dose to normal structures. 
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Purpose: Respiratory gating (RG) has been postulated as a 
method of reducing the irradiation of normal lung during SABR. 
RG refers to tumour treatment only during a specific phase or 
amplitude of the breathing cycle, in distinction to non-gated 
(NG) free-breathing delivery. The inability to visualize the 
tumour during RG with most systems has led to the hypothesis 
that geometric misses could occur, leading to a lower rate of 
local control (LC). The goal of this study was to assess oncological 
outcomes in patients receiving RG versus NG treatments.  
Methods and Materials: Outcomes for patients treated with 
SABR in 2010-15 for either primary non-small cell lung cancer 
(NSCLC) or metastatic disease were reviewed. Patients received 
a risk-adapted approach, using 3, 5, or 8 fractions (all with BED 
> 100 Gy10) depending on tumour size and location. Tumour 
motion was assessed using 4D-CT. RG was generally used when 
tumour motion was > 7 mm, with RG treatment delivered during 
end-expiration. Outcomes for RG and NG groups were estimated 
using Kaplan-Meier analyses, with propensity matching (in a 1:1 
ratio with a caliper width of 0.20) to control for baseline 
differences. 
Results: One hundred and nine patients were treated for primary 
NSCLC and 39 for oligometastatic cancers. Median follow up was 
17 months. Median age was 75 (range 42-94), most were male 
(56%), median FEV1 was 71% predicted (range 23-127% 
predicted), and median age-adjusted Charlson score was 7 
(range 3-13). Most patients (85%) had one lesion treated. In the 
whole cohort, there were eight local failures (three-year local 
control rate 88%), and nine regional failures (three-year regional 
failure rate 85%). Tumour location was the strongest predictor of 
use of RG (59% for lower lobe tumours versus 15% for others). 
Patients who received RG were also more likely to be older, with 
more target lesions, a higher Charlson score, and larger targets 
(all p < 0.05); these differences were no longer significant after 
matching. Comparing RG versus NG outcomes in matched 
patients (n = 52 in each group), there were no differences in LC 
(p = 0.23) associated with delivery technique. 
Conclusions: The use of RG does not appear to adversely affect 
local control rates. Further research is needed to determine if 
dosimetric benefits of RG lead to clinically improved outcomes.  
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TOTAL BODY IRRADIATION WITH VMAT - A FOCUS ON SCROTAL 
SHIELDING  
Greg Pierce, Steve Angyalfi, Alana Hudson 
University of Calgary, Calgary, AB 
 
Purpose: Total body irradiation (TBI) is given as part of a 
conditioning regime for stem cell transplant. Methods of delivery 
are often labour intensive, not comfortable for the patient, and 
provide limited capabilities for shielding critical structures 
without compromising treatment goals of irradiating the whole 
body, including skin, to a uniform ± 10% of the prescription dose. 
For example, our previous technique involved full patient bolus 
packing at extended SSD using lateral treatment fields. The 
patient’s arms were used to provide attenuation for lungs, and 
there was no ability to shield the gonads without compromising 
the dose to the pelvic bones. 
Methods and Materials: At the Tom Baker Cancer Centre (TBCC), 
we have implemented a new total body irradiation method that 
delivers a uniform dose using volumetric modulated arc therapy 
(VMAT) through gantry speed and MLC motion optimization. The 
MLC motion is limited to shielding for the lungs and reducing hot 
spots, and consequently, plans are not highly modulated. This 
allows us to streamline the treatment planning and quality 
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assurance, to limit the required resources, and to reduce the 
effect of differences in patient positioning between the planning 
CT and treatment. The patient is treated both prone and supine 
under a 1 cm clear plastic sheet positioned 20 cm from their 
surface used to increase skin dose. The first patient treated using 
this technique at the TBCC was a 16-year-old male with sickle-
cell anemia. As gonadal shielding was desirable for this patient, 
our extended SSD lateral field technique was not an option. Our 
optimized VMAT technique allowed us to provide a reasonable 
amount of gonadal shielding using MLCs. 
Results:  Dose to the gonads was further reduced using a physical 
shield made of coated lead positioned above the gonads using an 
in-house designed device. The combined effect of these two 
types of shielding allowed us to reduce dose to testis from the 
prescription of 300 cGy to approximately 100 cGy, without over-
modulating the treatment fields or compromising dose 
uniformity to the rest of the body. 
Conclusions: In conclusion, a new TBI technique has been 
developed using VMAT delivery that is optimized to patient 
anatomy. In addition to a safe and more comfortable patient 
environment, this technique allows for shielding of organs at risk, 
if desired by the physician, as was the case for a recent patient 
at the TBCC – a pediatric sickle-cell anemia patient requiring 
scrotal shielding.
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Purpose:  Tumour metabolism is a promising area of cancer 
research which is investigated to develop strategies for PrCa 
prevention and sensitization to cytotoxic therapy. AMP-kinase 
(AMPK) is a master regulator of cellular metabolism and a well-
studied target for metabolism modulating therapeutics. It 
inhibits energy expenditure through anabolic events and 
stimulates substrate uptake and catabolic activities to increase 
energy availability. We showed that AMPK also senses genotoxic 
stress. It is activated downstream of Ataxia Telangiectasia 
Mutated (AMT) and leads to, i) induction of p53 and cyclin-
dependent kinase inhibitors p21cip1/p27kip1 and inhibition of 
cell cycle and proliferation and ii) blockade of protein 
biosynthesis and survival through inhibition of the AKT—mTOR 
pathway. 
We found the anti-diabetic biguanide metformin (MET) and the 
metabolite of aspirin Salicylate (SAL) activate AMPK through 
separate mechanisms and suppress de novo lipogenesis, which is 
required for cellular growth and cell division . Combined 
treatment with SAL + MET enhanced AMPK activity, suppressed 
lipogenesis and inhibited PrCa proliferation and clonogenic 
survival significantly more than each agent alone. Interestingly, 
retrospective studies link MET and aspirin with improved 
responses to RT. 
Methods and Materials:  Androgen sensitive (22RV1) and 
insensitive (PC3) PrCa cells were treated with SAL, MET and SAL+ 
MET without or with increasing doses of radiotherapy (RT) (0-8 
Gy) and were subjected to proliferation, clonogenic survival and 
immunoblotting (IB) experiments. Also, cells were grafted into 
flanks of immunosuppressed nude mice, treated with SAL, MET 
and SAL+MET without and with RT (10 Gy) and left to grow for 
eight weeks to investigate effects of treatment on tumour 
growth kinetics and biomarkers of response. 
Results:  SAL and MET caused a significant inhibition of 
proliferation and clonogenic survival in both cell lines, activated 
AMPK and inhibited the mTOR pathway. Combined treatment 
(SAL+ MET) produced synergistic activation of AMPK, inhibition 
of mTOR and PrCa clonogenic survival. SAL alone sensitized PrCa 
cells to RT and increase activation of the ATM-AMPK pathway. 
Importantly, the combined SAL+MET treatment enhanced 
significantly the sensitivity of PrCa cells to RT compared to each 
agent alone. Ongoing experiments evaluate the effects of 
combined SAL+ MET treatment on tumour growth kinetics.  
Conclusions:  Early results on the investigation of combined SAL+ 
MET treatment indicate that this may be a promising therapy 
against PrCa tumour growth and radio-resistance. The two agents 
are extensively-used, well-tolerated and economical 
therapeutics and there are no reports associating them with 
increase RT toxicity. If positive, our studies will generate the 
first basis for future rapid clinical investigation of combined SAL+ 
MET with RT in PrCa. 
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Purpose: Use of SBRT to treat metastatic tumours is increasing, 
despite no randomized evidence. This project reviews the 
outcomes of treating extracranial NSCLC metastases with SBRT 
from a single institution. 
Methods and Materials: One hundred and eight patients with 
metastatic NSCLC were treated between 2009 and 2015. 
Indications for treatment were: 1) oligometastases, where the 
goal was to irradiate all tumour sites; 2) oligoprogression, where 
the goal was to irradiate only tumours which were progressing 
while all other tumours were stable on observation or systemic 
therapy; and 3) for dominant tumours, where the goal was to 
optimize local control, even if other tumours were progressing. 
Outcomes of interest were local control (LC), overall survival 
(OS), progression-free survival (PFS), and time to change 
systemic therapy (TTCST). 
Results: Median age was 69.0 years. Median follow up time was 
11.3 months. Sixty-six patients were treated for oligometastases, 
20 for oligoprogression, and 22 for dominant tumour/local 
control. Thirteen patients had targeted oral therapy, and 51 had 
chemotherapy prior to SBRT. Eleven were on systemic therapy 
(four targeted oral therapy and seven chemotherapy) at time of 
SBRT. A total of 165 lesions were treated (44 lung, 60 spine, 27 
non-spine bone, 15 liver, 15 adrenal, four other sites). Median 
SBRT dose/fractions was 35 Gy/4 fractions. Median BED10 was 
59.5 Gy, although 61 lesions (37%) were treated with BED10 of ≥ 
100 Gy. LC at one year and two years was 80.2% and 64.4%, 
respectively. Univariate analyses revealed BED10 ≥ 100 Gy (p = 
0.0142), tumour size ≤ 4 cm (p = 0.0012), and lung tumour (p = 
0.0421) to predict for higher LC. Two year LC was 90.3% versus 
52.1% for tumours treated with BED10 ≥ 100 Gy versus < 100 Gy. 
Median OS was 27.3 months. Indication for treatment 
independently predicted for OS (p = 0.0045) with 
oligometastases patients living the longest, followed by 
oligoprogression, and then dominant tumour/local control 
(median OS of 39.3 months, 21.1 months, and 11.8 months, 
respectively). Median PFS was 4.4 months, with indication for 
treatment (p = 0.0013) being independently predictive (median 
PFS of 7.6 months, 3.2 months, and 2.3 months for 
oligometastases, oligoprogression, and dominant tumour/local 
control, respectively). Median TTCST was not reached for the 
whole cohort. The probability of starting or changing systemic 
therapy was 23.5% at one year. Indication for treatment was 
predictive (p = 0.0022), with the probability of changing systemic 
therapy strategy at one year being 11%, 43.9%, and 45.5% for 
patients treated for oligometastases, oligoprogression, and 
dominant tumour/local control, respectively. Seventeen 
patients (16%) received further SBRT at time of progression. 
Conclusions: In patients with NSCLC extracranial metastases 
treated with SBRT, those with oligometastases have the longest 
OS, PFS, and TTCST compared to those treated for 
